VolitionRx FY2025 revenue up 40% to $1.7M; net loss down 14%

VOLITIONRX LTD

2026-Q1 EPS reported -$0.97 revenue$985,076

Full-year revenue $1.7M (+40% YoY); Q4 revenue growth 133% vs prior year.
Operating expenses down $4.8M (17%); net cash used in ops $19.7M (-24%).
Received first order for Nu.Q Cancer assays for lung cancer clinical certification.
Nu.Q NETs assay included in French government-backed sepsis study (~$7.3M).
Subsequent to year end: raised $5.4M ATM equity, $1.9M convertible note, $1.0M non-dilutive.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

VOLITIONRX LTD reported full fiscal year 2025 results: revenue $1.7 million.

Period: full fiscal year 2025
Revenue: $1.7 million
Result: reported results

Exact text from the filing

Full-year revenue for 2025 was $1.7 million, representing growth of 40% over the previous year.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

VOLITIONRX LTD filing history →

Source: SEC EDGAR

accession 0001477932-26-001830

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.